Michelle L. E. Peake
Direktor/Vorstandsmitglied bei VIROPRO INC.
Profil
Michelle L.
E.
Peake is currently the Director at Viropro, Inc. since 2012 and the Chief Operating Officer at Alpha Biologics Ltd.
since 2009.
Previously, she was the Chief Executive Officer at Alpha Biologics Sdn.
Bhd.
in 2011.
Ms. Peake completed her undergraduate degree at Griffith University in 1993.
Aktive Positionen von Michelle L. E. Peake
Unternehmen | Position | Beginn |
---|---|---|
VIROPRO INC. | Direktor/Vorstandsmitglied | 19.10.2012 |
Alpha Biologics Ltd.
Alpha Biologics Ltd. Pharmaceuticals: MajorHealth Technology Alpha Biologics is a Contract Manufacturer of Biologics drugs for use in pre-clinical, Phase1 and 2 clinical trials, anywhere in the World. The life sciences industry is experiencing spiralling drug development costs that are making it increasingly difficult for biotech and pharma companies to survive, let alone prosper. Alpha Biologics has been established to address this issue by providing its clients with the opportunity to take their biologic drugs through the early clinical trial phases at a cost is easily justified. This avoids the abandonment of potential blockbuster drug programmes based simply on cost before it has been possible to demonstrate safety and early efficacy. It specialises in the production of mammalian cell secreted protein drugs, and it provide all of the necessary services required to develop and produce its clients' drugs in full compliance with U.S. and European cGMP guidelines. Its manufacturing base in Malaysia brings significant cost advantages to its customers due to the lower overhead costs compared with Europe or the U.S., whilst maintaining the highest standards of compliance. Its core team has extensive experience of designing, building and operating cGMP compliant facilities for biologic drugs in the U.S. and Europe. This core team has been strengthened by internationally trained and experienced staff from the World-wide biologics industry and academia. Its goal is to deliver drugs on time for clinical trials at a price that is affordable, thereby enabling its clients' to maintain strong drug development pipelines and realise maximum value from the investments in research and development. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Michelle L. E. Peake
Unternehmen | Position | Ende |
---|---|---|
Alpha Biologics Sdn. Bhd.
Alpha Biologics Sdn. Bhd. Pharmaceuticals: MajorHealth Technology Part of Viropro, Inc., Alpha Biologics Sdn. The company is based in Penang, Malaysia. Bhd. develops pharmaceutical products. Alpha Biologics Sdn. was acquired by Viropro, Inc. from Alpha Biologics Ltd. on July 12, 2011 for $29.76 million. | Vorstandsvorsitzender | - |
Ausbildung von Michelle L. E. Peake
Griffith University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
VIROPRO INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Alpha Biologics Sdn. Bhd.
Alpha Biologics Sdn. Bhd. Pharmaceuticals: MajorHealth Technology Part of Viropro, Inc., Alpha Biologics Sdn. The company is based in Penang, Malaysia. Bhd. develops pharmaceutical products. Alpha Biologics Sdn. was acquired by Viropro, Inc. from Alpha Biologics Ltd. on July 12, 2011 for $29.76 million. | Health Technology |
Alpha Biologics Ltd.
Alpha Biologics Ltd. Pharmaceuticals: MajorHealth Technology Alpha Biologics is a Contract Manufacturer of Biologics drugs for use in pre-clinical, Phase1 and 2 clinical trials, anywhere in the World. The life sciences industry is experiencing spiralling drug development costs that are making it increasingly difficult for biotech and pharma companies to survive, let alone prosper. Alpha Biologics has been established to address this issue by providing its clients with the opportunity to take their biologic drugs through the early clinical trial phases at a cost is easily justified. This avoids the abandonment of potential blockbuster drug programmes based simply on cost before it has been possible to demonstrate safety and early efficacy. It specialises in the production of mammalian cell secreted protein drugs, and it provide all of the necessary services required to develop and produce its clients' drugs in full compliance with U.S. and European cGMP guidelines. Its manufacturing base in Malaysia brings significant cost advantages to its customers due to the lower overhead costs compared with Europe or the U.S., whilst maintaining the highest standards of compliance. Its core team has extensive experience of designing, building and operating cGMP compliant facilities for biologic drugs in the U.S. and Europe. This core team has been strengthened by internationally trained and experienced staff from the World-wide biologics industry and academia. Its goal is to deliver drugs on time for clinical trials at a price that is affordable, thereby enabling its clients' to maintain strong drug development pipelines and realise maximum value from the investments in research and development. | Health Technology |